This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Selonsertib for Non-alcoholic Steatohepatitis (NASH)

< Back

Selonsertib for Non-alcoholic Steatohepatitis (NASH)


Gastrointestinal, Pancreatic and Liver Disease

May 2018

Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat is stored in the liver. This build-up of fat is not caused by heavy alcohol use. Two types of NAFLD are simple fatty liver and non-alcoholic steatohepatitis (NASH). Simple fatty liver and NASH are two separate conditions, and people typically develop one or the other. NASH is characterized by inflammation of the liver (hepatitis) and liver cell damage. Inflammation and liver cell damage can cause scarring (fibrosis) of the liver leading to cirrhosis. NASH may lead to other complications such as decompensated cirrhosis of the liver, in which the liver no longer functions, and liver cancer.
Selonsertib is an investigational oral small molecule inhibitor of ASK1, a protein that mediates inflammation, apoptosis (cell death) and fibrosis in settings of oxidative stress. Oxidative stress can be increased in many pathological conditions including liver diseases such as NASH. NASH currently has no effective treatment apart from lifestyle interventions. If licensed, selonsertib will offer a new treatment option for NASH as no effective pharmacological therapies currently exist.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts